行情

FPRX

FPRX

Five Prime
NASDAQ

实时行情|Nasdaq Last Sale

4.760
-0.030
-0.63%
盘后: 4.790 +0.03 +0.63% 17:17 08/13 EDT
开盘
4.800
昨收
4.790
最高
4.940
最低
4.610
成交量
31.34万
成交额
--
52周最高
7.34
52周最低
1.750
市值
1.74亿
市盈率(TTM)
-1.6024
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测FPRX价格均价为8.40,最高价位11.00,最低价为5.00。

EPS

FPRX 新闻

更多
Five Prime Therapeutics EPS beats by $0.22, misses on revenue
Five Prime Therapeutics (NASDAQ:FPRX): Q2 GAAP EPS of -$0.48 beats by $0.22. Revenue of $3.42M (+2.7% Y/Y) misses by $1.93M. Press Release
seekingalpha · 08/07 01:30
Five Prime Therapeutics (FPRX) Reports Q2 Loss, Misses Revenue Estimates
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 31.43% and -22.76%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/07 00:30
Five Prime Therapeutics Reports Second Quarter 2020 Results
Five Prime Therapeutics Reports Second Quarter 2020 Results
Business Wire · 08/06 20:05
Five Prime Therapeutics (FPRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:33
Five Prime Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Five Prime Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Business Wire · 07/29 23:00
Five Prime Therapeutics Announces Timing of Its Second Quarter 2020 Results Conference Call
Five Prime Therapeutics Announces Timing of Its Second Quarter 2020 Results Conference Call
Business Wire · 07/29 22:30
Will Five Prime Therapeutics (FPRX) Report Negative Q2 Earnings? What You Should Know
Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/29 16:33
Biotech Bonanza - Second Half Outlook
Seeking Alpha · 07/28 12:24

所属板块

生物技术和医学研究
+0.99%
制药与医学研究
-0.06%

热门股票

代码
价格
涨跌幅

FPRX 简况

Five Prime Therapeutics, Inc.(Five Prime)是一家临床开发阶段的生物技术公司。该公司专注于探索和开发蛋白质疗法。该公司有3种处于临床开发阶段的候选药物,这些候选药物涵盖多种潜在的适应症。该公司主要在肿瘤免疫治疗领域进行临床和开发研究、研制新药物并和其他机构合作探索开发新药物和新技术。该公司聘请第三方合作机构帮助开发临床项目中的伴随诊断技术。该公司的候选药物包括FPA008、FPA144和FP-1039 (GSK3052230)。FPA008是抑制集落刺激因子-1(CSF1)受体(CSF1R)的抗体。 FPA144是抑制纤维母细胞生长因子受体2b(FGFR2b)的抗体。 FP-1039是一种用于捕获和抑制致癌纤维母细胞生长因子(FGF)的蛋白质治疗剂。
展开

微牛提供Five Prime Therapeutics Inc(NASDAQ-FPRX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的FPRX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易FPRX股票基本功能。